Cartalax common uses, half-life, side effects and more

Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp. It belongs to the Russian short peptide bioregulator family and is sold for cartilage and joint support. Russian-speaking markets sell it as a registered food supplement in capsule and sublingual drop form. That registration covers safety and labeling as a food rather than any proof that it works. Western sellers offer lyophilized vials for injection as research chemicals. No injectable form is registered anywhere. It is not an approved medicine in the United States, the European Union, or Canada.

• Joint stiffness and mobility
• Cartilage and connective tissue support
• Osteoarthritis symptoms
• Bone and cartilage metabolism claims
• Longevity bioregulator courses

Daily during courses of 10 to 30 days, repeated after 3 to 6 months

Oral capsules hold 0.1 mg of peptide each. Label directions are 1 to 2 capsules 1 to 2 times daily with food for a total of 0.1 to 0.4 mg per day. Sublingual drops hold 0.1 mg per mL. Directions are 5 to 6 drops under the tongue 3 to 4 times daily taken 10 to 15 minutes before food for a total of 75 to 140 mcg per day. Both courses run about a month and repeat after 3 to 6 months. Russian users often exceed the labeled amount and run courses back to back instead of leaving the gap. No injected dose is established. A handful of first-hand reports describe 1 to 2 mg daily by injection for about 20 days. That is roughly ten times the oral daily amount by a route that skips digestion. The only published human injection data is a patent report that gave 1 mcg, 10 mcg, or 5 mg intramuscularly once daily for 20 days, assigned by age and joint severity rather than by body weight.

• A capsule weighs about 200 mg and holds 0.1 mg of peptide
• Sublingual drops are taken 10 to 15 minutes before eating
• The registered capsule and drop products are a different article from the injection vials sold in the West
• The sublingual liquid also comes in glass ampules opened with a syringe that only moves the liquid into a container before it goes under the tongue

No plasma half-life has been established for Cartalax in any species. Absorption claims on product pages rest on a computer modeling study of peptide transporters rather than on any measurement.

• Generalized itching after injection in the only first-hand accounts that mention a reaction
• Digestive upset with the tablet form that the label flags for people prone to bowel trouble
• Reactions to capsule fillers including lactose and polysorbate 80 in one manufacturer's product

Cartalax is the tripeptide Ala-Glu-Asp. It has no known receptor target. The proposed action is that it enters cells and changes which genes are active in connective tissue. Human mesenchymal stem cells aged in culture produced more SOX9, aggrecan, type II collagen, and COMP after exposure to it. Those four are markers and building blocks of cartilage. It raised IGF1 expression in aging stem cell cultures alongside two other short peptides. Rat skin fibroblast work found it lowered a cell-death marker and a tissue-degrading enzyme. It also raised expression of NF-kB. The researchers who reported that suggested it could speed stem cell aging as well as calm joint inflammation. No study has shown cartilage repair in a living person.

The evidence is thin and nearly all of it comes from one research group. Cell culture work in human stem cells and rat skin fibroblasts is the strongest direct evidence for this peptide. The only human data sits inside a patent application. That report treated 29 people with knee osteoarthrosis against 12 given saline. It assigned the dose by age and severity rather than at random. It described less pain and better movement in 54.5% to 62.7% of cases without statistics or a control response rate. X-rays showed no significant change. The same patent reports animal toxicity testing in mice, rats, and guinea pigs that found no toxic effects. The authors of the cell studies are named inventors on that patent. No unaffiliated group has replicated any of the findings. No registered product label carries a side-effects section. Tolerability has never been systematically monitored. No pharmacokinetic study exists in any species. Russian consumer reviews of the capsules number in the low hundreds and are mostly positive. Independent reviews of the wider peptide family run more negative than positive. Russian doctors who publish a joint protocol for this peptide family reach for the natural cartilage extract rather than Cartalax.

• A vial labeled AEDL holds a different peptide aimed at the lungs rather than Cartalax
• Purity certificates on injection vials confirm the material is clean without confirming which peptide it contains
• No injected dose has ever been established and no safety monitoring of injected use exists
• A single 20 mg injection vial holds about a hundred times the daily amount the oral product delivers
• Product instructions list pregnancy, breastfeeding, and intolerance to the ingredients as contraindications
• Severe allergic swelling of the face and hands needing emergency care has been reported by people taking several peptides from this family at once